Mary E. Godwin Sells 35,000 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Nautilus Biotechnology Stock Down 1.2 %

Shares of NASDAQ:NAUT traded down $0.03 during midday trading on Wednesday, hitting $2.87. The stock had a trading volume of 94,625 shares, compared to its average volume of 74,260. The business’s 50-day simple moving average is $2.57 and its 200-day simple moving average is $2.59. Nautilus Biotechnology, Inc. has a 12 month low of $2.19 and a 12 month high of $3.62. The company has a market cap of $359.51 million, a P/E ratio of -5.22 and a beta of 1.20.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter last year, the business earned ($0.13) EPS. As a group, equities analysts predict that Nautilus Biotechnology, Inc. will post -0.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NAUT. Guggenheim initiated coverage on Nautilus Biotechnology in a research note on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective for the company. Jefferies Financial Group started coverage on Nautilus Biotechnology in a research report on Monday, June 3rd. They set a “hold” rating and a $3.00 price target on the stock.

Institutional Trading of Nautilus Biotechnology

A number of institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of Nautilus Biotechnology by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after acquiring an additional 14,100 shares during the period. Dimensional Fund Advisors LP lifted its position in Nautilus Biotechnology by 19.8% during the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock worth $1,345,000 after purchasing an additional 94,908 shares during the period. Clarius Group LLC grew its stake in Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after buying an additional 16,661 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Nautilus Biotechnology by 35.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after buying an additional 4,239 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Nautilus Biotechnology by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock worth $8,407,000 after acquiring an additional 29,604 shares during the period. Institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.